Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system

Mod Pathol. 2008 Oct;21(10):1278-80; author reply 1280-1. doi: 10.1038/modpathol.2008.131.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Biomarkers, Tumor* / genetics
  • Biomarkers, Tumor* / metabolism
  • Breast Neoplasms / diagnosis*
  • False Positive Reactions
  • Female
  • Humans
  • Immunohistochemistry* / methods
  • Immunohistochemistry* / standards
  • In Situ Hybridization, Fluorescence / methods*
  • Practice Guidelines as Topic*
  • Receptor, ErbB-2* / genetics
  • Receptor, ErbB-2* / metabolism
  • Reproducibility of Results
  • Research Design / standards*

Substances

  • Biomarkers, Tumor
  • Receptor, ErbB-2